May 5, 2025 09:29 AM EDTUpdated 01:47 PM

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

Lei Lei Wu

News Reporter

Johnson & Johnson’s gene therapy for a genetic disease that leads to vision loss called X-linked retinitis pigmentosa (XLRP) failed a pivotal trial, according to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Bristol Myers to lay off over 500 workers in New Jersey

Early bits of in vivo CAR-T human data emerge from biotech trials in China

Recursion cuts nearly half of its pipeline, including its most advanced program

PTC's Huntington’s study succeeds, but accelerated approval uncertain

Unity lays off 'all' workers; Novo to get FDA decision on oral Wegovy this year

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

News Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial